BRAINTREE, Mass.--(EON: Enhanced Online News)--Paragonix Technologies, Inc. today announced plans to present the SherpaPak™ Organ Transport Systems during the ASTS 17th Annual State of the Art Winter Symposium to be held in Miami, FL, between 26 to 29 January 2017. The SherpaPak™ Cardiac Transport System1,2 and SherpaPak™ Kidney Transport System3,4 combine innovative cooling technology with a safe, consistent method for cold ischemic storage and transport of donor hearts and kidneys to recipients for implantation. The ASTS Winter Symposium is organized by the American Society of Transplant Surgeons and is focused on innovative science to combat the shortage of life-saving donor organs.
“Cardiac transplantation continues to be the gold standard for the treatment of end-stage heart failure. However, the number of potential transplants far exceeds the number of donors.”
Dr. Lisa Anderson, President and Chief Operating Officer, for Paragonix commented, “We are looking forward to discussing the SherpaPak™ Organ Transport Systems with the clinical community during the upcoming 2017 ASTS Winter Symposium. Since launching the SherpaPak™ product portfolio in 2016, the Paragonix team has been meeting with many transplant centers across the United States and we are excited that SherpaPak™ has generated such great clinical demand. We look forward to the opportunity to support many more transplant centers and organ procurement organizations across the nation with SherpaPak™ and organ preservation solutions for both donor kidneys and hearts.”
Paragonix previously announced January 4, 2017 an exclusive supply agreement with Sanbor Medical for the Manufacture and Assembly of SherpaPak™ Organ Transport Systems
Paragonix previously announced December 22, 2016 an exclusive distribution agreement with Bio Instruments for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in the Midwestern United States
Paragonix previously announced November 9, 2016 an exclusive distribution agreement with Pacific West Medical Sales for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in California
Paragonix previously announced June 29, 2016 a Product Supply Agreement with Waters Medical Systems LLC, for Waters IGL and Celsior® Cold Storage Solutions for Use With the SherpaPak™ Kidney Transport System and SherpaPak™ Cardiac Transport System
Paragonix and Essential Pharmaceuticals LLC previously announced June 28, 2016, a Product Supply Agreement for Custodiol® HTK Organ Preservation Solution for Use With the SherpaPak™ Cardiac Transport System and SherpaPak™ Kidney Transport System
Paragonix previously announced on July 23, 2015, Publication of “Innovative Cold Storage Of Donor Organs Using The Paragonix SherpaPak™ Devices"5
Paragonix previously announced on February 9, 2015, Innovative Tracking Technology For Real-Time, National Location Tracking of Donor Organs
About the American Society of Transplant Surgeons
The American Society of Transplant Surgeons represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. Their mission is to advance the art and science of transplant surgery through leadership, advocacy, education, and training.
About the Paragonix SherpaPak™ and SherpaPerfusion™ Cardiac Transport
Currently, the availability of cardiac transplantation is governed by the “ischemic time”, that being, the elapsed time from heart donation to recipient implantation. According to The International Society Of Heart and Lung Transplantation (“ISHLT”) guidelines6 for the care of heart transplant recipients, the projected ischemic time should not exceed 4 hours7,8, limiting the distance available to transport a donor heart. Paragonix SherpaPak™ Cardiac Transport System is fully disposable, eliminating problems associated with maintenance, device transport and contamination. The Paragonix SherpaPerfusion™ Cardiac Transport System combines innovative oxygenated perfusion of organs and safe organ storage with the ultimate goal of extending ischemic time to 12 hours, significantly altering the transportation range of donor hearts.
About the Cardiac Transplantation Market
Cardiac transplantation is considered the gold standard therapy for patients in end-stage heart failure.9 With over 5.8 million Americans currently diagnosed with heart failure (HF), growing at an annual rate of 400,000 per year10, there is a persistent need to provide end-stage heart failure support to this expanding population. Estimates of the prevalence of symptomatic HF in the general European population are similar to those in the United States.11 The annual economic burden of treating heart failure exceeds $34.4 billion12, over 50% of which is due to the cost of hospitalization.13 The financial demands associated with transplantation are considerable. The estimated first year costs for heart transplant are $997,700, and subsequent annual costs can easily exceed $30,00014. In the United States, around 30,000 people die annually from end-stage heart disease. As of June 1, 2012, 3,203 patients in the United States are on the waiting list for a heart transplant15. Based on 2011 data, just over 2,300 patients will receive a live-saving transplant each year, which is reflective of the enormous donor heart shortage. These data, however, only seem to represent the tip of the iceberg. Assuming that up to 50,000 people with end-stage heart failure are candidates for transplantation16, maximization of donor organ utilization has enormous potential in cardiac transplantation.
About Paragonix Technologies, Inc.
Based in Massachusetts and founded in 2010, Paragonix Technologies Inc., is a privately held medical device company innovating the Paragonix SherpaPak™ and SherpaPerfusion™ Organ Transport System, a novel, single-use organ preservation device to improve donor organ quality. Paragonix has established a pipeline of donor organ transport devices that address the current donor organ shortage by maximizing donor organ utilization, improving donor organ quality and extending donor organ transport throughout the entire United States.
1 The SherpaPak™ Cardiac Transport System is protected by patents, both issued and pending
2 The SherpaPak™ Cardiac Transport System has received FDA 510(k) pre-market clearance
3 The SherpaPak™ Cardiac Transport System is protected by patents, both issued and pending
4 The SherpaPak™ Cardiac Transport System has received FDA 510(k) pre-market clearance
5 Michel et al. Heart, Lung and Vessels; 2015;7(3):246-55
6 ISHLT Guidelines for the Care of Heart Transplant Recipients, Task Force 1: Peri-operative Care of the Heart Transplant Recipient (Aug. 4, 2010)
7 J Heart Lung Transplant 2001; 20(2):212.
8 J Am Coll Cardiol 2004; 43(9):1553-1561.
9 Datamonitor senior cardiovascular analyst Dr. Sergey Ishin. “Cardiac transplantation continues to be the gold standard for the treatment of end-stage heart failure. However, the number of potential transplants far exceeds the number of donors.” http://about.datamonitor.com/media/archives/314
10 Circulation 2010;121:e46-e215
12 Circulation 2011;123(8):933-944
13 Circulation 2007;115(5)